Health + Wellness
stem-cell therapy from athersys shows promise in brain injuries and heart attacks
The October issue of the journal Experimental Neurology reports
on a study showing that MultiStem, a patented adult stem cell therapy
product from Cleveland-based biopharmaceutical firm Athersys Inc., mitigated the damage of traumatic brain injuries in lab experiments.
MultiStem uses multipotent adult progenitor cells, or MAPC, which "are obtained from the bone marrow or other tissue sources of healthy, consenting adult donors," according to an Athersys release. In an abstract of the study, the researchers explain, "Traumatic brain injury causes … an increase in circulating immune cells leading to increased blood brain barrier permeability. The intravenous injection of MAPC preserves … the integrity of the blood brain barrier."
As an unrelated 2007 Science Daily article explained, "The cells that make up the blood-brain barrier help the brain and immune system communicate. … Changes to the blood-brain barrier could give important clues about injuries to the central nervous system and the growth of tumors."
MultiStem appears to be an unusually versatile therapy. The same week that the Experimental Neurology report was released,
Athersys presented findings from clinical trials with heart attack patients at Transvascular Cardiovascular Therapeutics Conference in Washington, D.C. That ongoing work involves Dr. Marc Penn, Director of Cardiovascular Cell Therapy at the Cleveland Clinic. Athersys CEO Gil Van Bokkelen notes that while the recent trials were designed primarily to test safety, "we also saw clear and compelling signs that patients were experiencing improvement in heart function."
Van Bokkelen says Athersys and its many partners, including Pfizer, are excited about the potential of MultiStem as a "very powerful multifactor delivery system" that can treat a wide variety of patients.
Source: Athersys
Writer: Frank W. Lewis
MultiStem uses multipotent adult progenitor cells, or MAPC, which "are obtained from the bone marrow or other tissue sources of healthy, consenting adult donors," according to an Athersys release. In an abstract of the study, the researchers explain, "Traumatic brain injury causes … an increase in circulating immune cells leading to increased blood brain barrier permeability. The intravenous injection of MAPC preserves … the integrity of the blood brain barrier."
As an unrelated 2007 Science Daily article explained, "The cells that make up the blood-brain barrier help the brain and immune system communicate. … Changes to the blood-brain barrier could give important clues about injuries to the central nervous system and the growth of tumors."
MultiStem appears to be an unusually versatile therapy. The same week that the Experimental Neurology report was released,
Athersys presented findings from clinical trials with heart attack patients at Transvascular Cardiovascular Therapeutics Conference in Washington, D.C. That ongoing work involves Dr. Marc Penn, Director of Cardiovascular Cell Therapy at the Cleveland Clinic. Athersys CEO Gil Van Bokkelen notes that while the recent trials were designed primarily to test safety, "we also saw clear and compelling signs that patients were experiencing improvement in heart function."
Van Bokkelen says Athersys and its many partners, including Pfizer, are excited about the potential of MultiStem as a "very powerful multifactor delivery system" that can treat a wide variety of patients.
Source: Athersys
Writer: Frank W. Lewis
cervilenz inc. offers another tool for doctors and pregnant women
Five months after the commercial launch of its medical device, CerviLenz Inc. of Chagrin Falls is ramping up for a national marketing push in the third quarter.
The wand-like CerviLenz measures the vaginal cervical length of pregnant women showing signs of preterm labor. In August, Ob.Gyn. News reported that in a study involving 52 women, CerviLenz was "similar in efficacy" to another widely used test that, unlike a CerviLenz test, requires lab work.
"Immediate and quantifiable measures of cervical length using the CerviLenz probe may be less variable than the most common way of measuring — by digital exam — and speedier than waiting for fetal fibronectin [test] results," according to Ob.Gyn. News.
The device helps reduce the guesswork in treatment: The article notes that only 21-27 percent of women with symptoms of preterm labor will actually deliver prematurely. And, "In asymptomatic women, cervical length shorter than 25 mm has been linked to a sixfold increase in risk for preterm birth."
About 25 hospitals are currently evaluating the product. "The hospital purchasing process is really complicated," with multiple rounds of testing, says Melanie Sweeney, CerviLenz Inc.'s director of marketing. But the company should soon start receiving the feedback it will need for a major sales push.
CerviLenz Inc.'s backers include Cleveland-based JumpStart Inc., North Coast Angel Fund of Mayfield Heights and Chrysalis Ventures, which has a Cleveland office.
Source: CerviLenz Inc.
Writer: Frank W. Lewis
The wand-like CerviLenz measures the vaginal cervical length of pregnant women showing signs of preterm labor. In August, Ob.Gyn. News reported that in a study involving 52 women, CerviLenz was "similar in efficacy" to another widely used test that, unlike a CerviLenz test, requires lab work.
"Immediate and quantifiable measures of cervical length using the CerviLenz probe may be less variable than the most common way of measuring — by digital exam — and speedier than waiting for fetal fibronectin [test] results," according to Ob.Gyn. News.
The device helps reduce the guesswork in treatment: The article notes that only 21-27 percent of women with symptoms of preterm labor will actually deliver prematurely. And, "In asymptomatic women, cervical length shorter than 25 mm has been linked to a sixfold increase in risk for preterm birth."
About 25 hospitals are currently evaluating the product. "The hospital purchasing process is really complicated," with multiple rounds of testing, says Melanie Sweeney, CerviLenz Inc.'s director of marketing. But the company should soon start receiving the feedback it will need for a major sales push.
CerviLenz Inc.'s backers include Cleveland-based JumpStart Inc., North Coast Angel Fund of Mayfield Heights and Chrysalis Ventures, which has a Cleveland office.
Source: CerviLenz Inc.
Writer: Frank W. Lewis